# Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients

> **NCT00224055** · PHASE4 · COMPLETED · sponsor: **Watson Pharmaceuticals** · enrollment: 89 (actual)

## Conditions studied

- Anemia, Iron-Deficiency
- Kidney Failure, Chronic

## Interventions

- **DRUG:** Sodium Ferric Gluconate Complex in Sucrose Injection
- **DRUG:** Ferrous sulfate tablets

## Key facts

- **NCT ID:** NCT00224055
- **Lead sponsor:** Watson Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2004-09
- **Final completion:** 2004-09
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2012-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00224055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00224055, "Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00224055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*